Advanced in Sepsis

Dr. John M. Pullman

Infectious Disease | Intensive Care Medicine
Mercury Street Medical Group PLLC
300 W Mercury St, 
Butte, MT 
 (1309.7 mi)
Accepting New Patients
Advanced in Sepsis
Mercury Street Medical Group PLLC
300 W Mercury St, 
Butte, MT 
 (1309.7 mi)
OverviewInsuranceLocationsClinical Research

Overview

John Pullman is an Infectious Disease specialist and an Intensive Care Medicine provider in Butte, Montana. Dr. Pullman and is rated as an Advanced provider by MediFind in the treatment of Sepsis. His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, Osteomyelitis, and Familial Chronic Mucocutaneous Candidiasis. Dr. Pullman is currently accepting new patients.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Sepsis.

Specialties
Infectious Disease
Intensive Care Medicine
Licenses
Internal Medicine in MT
Hospital Affiliations
Community Hospital Of Anaconda
St James Healthcare
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  PacificSource
  •  Humana

Locations

MERCURY STREET MEDICAL GROUP PLLC
300 W Mercury St, Butte, MT 59701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Comparator-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CRS3123 Compared With Oral Vancomycin in Adults With Clostridioides Difficile Infection
A Phase 2, Randomized, Double-Blind, Comparator-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CRS3123 Compared With Oral Vancomycin in Adults With Clostridioides Difficile Infection
Enrollment Status: Active_not_recruiting
Publish Date: February 22, 2024
Intervention Type: Drug
Study Drug: CRS3123
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Enrollment Status: Suspended
Publish Date: February 08, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
Enrollment Status: Completed
Publish Date: March 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

18 Total Publications

Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials.
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials.
Journal: Critical care (London, England)
Published: July 24, 2024
Similar Doctors
Experienced in Sepsis
Dr. Anne M. Anglim
Hospital Medicine | Infectious Disease
Experienced in Sepsis
Dr. Anne M. Anglim
Hospital Medicine | Infectious Disease

St Peters Health

2475 E Broadway St, 
Helena, MT 
 (47.3 mi)
406-447-2828
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anne Anglim is a Hospital Medicine specialist and an Infectious Disease provider in Helena, Montana. Dr. Anglim and is rated as an Experienced provider by MediFind in the treatment of Sepsis. Her top areas of expertise are Infectious Arthritis, Sepsis, Bacterial Gastroenteritis, Vertebroplasty, and Bone Graft. Dr. Anglim is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile